Nasdaq
$64.60▲ 0.84%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.92BShares out 29.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 9.18After-hours26.09.19 05:434Ownership#●●●
GeneDx Holdings Corp.
Insider Katherine Stueland of GeneDx Holdings Corp. reported a change in beneficial ownership of securities as of September 16, 2026. This filing is a Form 4 statement detailing the insider's updated equity position.…more
$64.60+0.84%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.18After-hours26.09.19 05:394Ownership
GeneDx Holdings Corp.
Insider Kevin Feeley of GeneDx Holdings Corp. reported a change in beneficial ownership of securities as of September 16, 2026. This filing serves as a Form 4 statement detailing the executive's updated stock holdings.…more
$64.60+0.84%vs prev closeView filingShare - 9.18After-hours26.09.19 05:374Ownership
GeneDx Holdings Corp.
Insider Thomas Fuchs of GeneDx Holdings Corp. reported a change in beneficial ownership of securities as of September 17, 2026. This filing formalizes the insider's transaction details in accordance with Form 4 requirements.…more
$64.60+0.84%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.20Pre-market26.10.20 21:37#●●●#●●●
GeneDx to Enhance Genomic Testing with Long-Read Sequencing
GeneDx plans to integrate long-read whole genome sequencing to improve the detection of complex genetic variations and accelerate clinical diagnosis. The company will launch an early access program by year-end to leverage this technology for more precise patient outcomes.…more
$64.60+0.84%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.19After-hours26.10.20 05:06
●●●●●●●● ●●●●● ●●●●●●
GeneDx presented 27 research abstracts at the American Society of Human Genetics 2026, highlighting the value of exome and genome sequencing as a standard of care. While the research strengthens the clinical case for genomic medicine, it does not provide immediate financial or contractual impacts.…more
$64.60+0.84%vs prev closeShareBenzinga - 10.7Pre-market26.10.07 21:36
●●●●●●●● ●●●●● ●●●●●●
GeneDx will present new findings at the International Consortium on Newborn Sequencing, highlighting progress in making genomic newborn screening scalable and accessible. The presentation underscores the company's efforts to integrate genomic data into proactive healthcare.…more
$64.60+0.84%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report